On July 30, the State Drug Administration held a symposium on strengthening the drug clinical trial supervision area in Xiong'an New District, Hebei. Yang Sheng, member of the party group and deputy director of the State Drug Administration, attended the meeting and delivered a speech. The conference exchanged information on drug clinical trial supervision work, analyzed the current situation facing innovative drug development and clinical trial supervision, and put forward requirements for further strengthening the drug clinical trial supervision system and doing a good job in drug clinical trial supervision. The meeting demanded that local drug regulatory authorities should strictly implement the work arrangements of the State Drug Administration, solidly push for the implementation of the newly revised “Drug Administration Law Implementation Regulations” and “Drug Clinical Trial Quality Management Standards”, continue to consolidate the quality management system of supervisory agencies, continuously strengthen daily supervision and registration and verification, and serve the construction of clinical trial institutions ahead of time to help the high-quality development and high level of safety of drug clinical trials in China.

On July 30, the State Drug Administration held a symposium on strengthening the drug clinical trial supervision area in Xiong'an New District, Hebei. Yang Sheng, member of the party group and deputy director of the State Drug Administration, attended the meeting and delivered a speech. The conference exchanged information on drug clinical trial supervision work, analyzed the current situation facing innovative drug development and clinical trial supervision, and put forward requirements for further strengthening the drug clinical trial supervision system and doing a good job in drug clinical trial supervision. The meeting demanded that local drug regulatory authorities should strictly implement the work arrangements of the State Drug Administration, solidly push for the implementation of the newly revised “Drug Administration Law Implementation Regulations” and “Drug Clinical Trial Quality Management Standards”, continue to consolidate the quality management system of supervisory agencies, continuously strengthen daily supervision and registration and verification, and serve the construction of clinical trial institutions ahead of time to help the high-quality development and high level of safety of drug clinical trials in China.